March 19, 2021 -- Waters has introduced a new peptide multiattribute method (MAM) workflow for its BioAccord liquid chromatography-mass spectrometry system.
The new MAM workflow will enable drug development, manufacturing, and quality control scientists to monitor the efficacy and safety of monoclonal antibodies and other protein-based drugs through analysis of critical quality attributes (CQAs). The peptide MAM workflow monitors product variants, product degradation and impurities, and process stability-indicating modifications.
New peptide multiattribute method (MAM) workflow for the BioAccord LC-MS System. Image courtesy of Waters.
The BioAccord system is part of the waters_connect informatics platform, which provides a single, sensitive multiplexed method to accurately assess the most important attributes of protein-based drugs. The BioAccord system pairs Waters' Acquity ultraperformance (UP) LC I-class PLUS with the Acquity RDa mass detector.
The system also has workflows for other routine analyses of biotherapeutics including peptide mapping, intact/subunit mass analysis, released glycan profiling, and oligonucleotide mass confirmation.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
